News
ARVN
7.44
-0.40%
-0.03
Insider Sale: Chief Scientific Officer of $ARVN Sells 2,583 Shares
NASDAQ · 3d ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga · 3d ago
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
NASDAQ · 5d ago
Weekly Report: what happened at ARVN last week (0609-0613)?
Weekly Report · 5d ago
Arvinas Unveils Promising ARV-393 Data at EHA Congress
TipRanks · 06/13 11:28
Arvinas presents preclinical data from studies of ARV-393
TipRanks · 06/13 11:05
Arvinas Presents Data From Preclinical Studies Of ARV-393, PROTAC B-Cell Lymphoma 6 Protein Degrader, At EHA 2025 Congress
Benzinga · 06/13 11:04
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
Barchart · 06/13 06:00
Barclays Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)
TipRanks · 06/12 07:15
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga · 06/09 13:19
Weekly Report: what happened at ARVN last week (0602-0606)?
Weekly Report · 06/09 09:05
Arvinas R&D President Ian Taylor Resigns
TipRanks · 06/06 21:00
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Benzinga · 06/06 14:18
Pfizer, Arvinas submit marketing application for vepdegestrant to the FDA
Seeking Alpha · 06/06 13:42
Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer
Dow Jones · 06/06 11:52
Arvinas and Pfizer Submit New Drug Application
TipRanks · 06/06 11:30
Arvinas Announces Submission Of NDA With Its Partner Pfizer For Vepdegestrant
NASDAQ · 06/06 11:23
Arvinas announces submission of NDA to FDA for vepdegestrant
TipRanks · 06/06 11:10
Arvinas Submits NDA To FDA With Partner Pfizer For Vepdegestrant For Treatment Of Patients With ER+/HER2- ESR1-Mutated Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine-Based Therapy
Benzinga · 06/06 11:04
ARVINAS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA FOR VEPDEGESTRANT FOR PATIENTS WITH ESR1-MUTATED ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Reuters · 06/06 11:00
More
Webull provides a variety of real-time ARVN stock news. You can receive the latest news about Arvinas through multiple platforms. This information may help you make smarter investment decisions.
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.